Results 181 to 190 of about 1,577,423 (359)
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Genomics and drug discovery [PDF]
, 2002 Genomics represents a new tool in drug discovery. Microbial genomics have been at the forefront of a new era of whole cell molecular biology because genomic data provides a quantum leap in available genetic data.
Hazell, Stuart L.
core
Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining
Molecular Oncology, EarlyView.IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis +3 more
wiley +1 more source
Collaborating with Central Cancer Registries for Public Health Genomics [PDF]
Central cancer registries make up a comprehensive national network of population-based cancer surveillance to monitor cancer cases at local, state, and national levels.
core
Molecular Oncology, EarlyView.Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens +6 more
wiley +1 more source
Finding novel vulnerabilities of hypomorphic BRCA1 alleles
Molecular Oncology, EarlyView.Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder +10 more
wiley +1 more source
Office of Public Health Genomics: State Public Health Genomics Programs: Implementing Evidence-Based Genomic Tests and Family Health History [PDF]
Since 2008, CDC, through the Office of Public Health Genomics (OPHG) and the Division of Cancer Prevention and Control (DCPC), has supported state genomics programs in Michigan, Oregon, and more recently Georgia, to implement evidence-based genomics ...
core
Functional Genomics for Plant Breeding 3.0
Functional genomics, as a scientific discipline, has significantly transformed the landscape of plant breeding in recent years [...
José Manuel Cruz-Rubio, Fatemeh Maghuly
core +1 more source
Stacks: an analysis tool set for population genomics
Molecular Ecology, 2013 J. Catchen +4 more
semanticscholar +1 more source
MITF maintains genome stability in nonmelanocyte lineages
Molecular Oncology, EarlyView.MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir +13 more
wiley +1 more source